The Trump administration is currently considering Dr. Norman “Ned” Sharpless, a former health official, for the position of Food and Drug Administration (FDA) chief. Dr. Sharpless, who previously led the National Cancer Institute during President Trump’s first term, is known for his critical stance on some vaccine policies advocated by Health and Human Services Secretary Robert F. Kennedy Jr.

Potential Shift in Health Leadership

Dr. Sharpless, who briefly served as acting FDA commissioner in 2019, is among several candidates being vetted for the permanent role. His consideration reflects the administration’s potential move away from the “Make America Healthy Again” (MAHA) movement, which has seen its influence decline as the administration seeks to stabilize the health department ahead of the midterms.

Since leaving government service in 2022, Dr. Sharpless has co-founded a venture capital fund focused on biotechnology and has been a professor at the University of North Carolina School of Medicine. He has also publicly opposed recent changes to FDA vaccine policies, emphasizing the importance of maintaining a regulatory model that ensures vaccine safety and effectiveness.

Broader Implications for FDA Leadership

In addition to Dr. Sharpless, the administration is also considering Richard Pops, a pharmaceutical executive, and current acting FDA commissioner Kyle Diamantas for the role. While Diamantas has impressed officials with his leadership, his limited experience with drug issues may affect his candidacy.

The search for a new FDA chief is part of a broader effort to fill key vacancies within the Department of Health and Human Services (HHS) and address public health challenges. The administration has been moving towards appointing more conventional leaders, as seen with the recent nomination of Erica Schwartz to lead the Centers for Disease Control and Prevention.

The decision on the new FDA chief will be crucial, especially as the administration navigates contentious issues such as the regulation of the abortion pill mifepristone. The choice will need to balance the expectations of both Secretary Kennedy and President Trump, while also securing confirmation in a closely divided Senate.

Original reporting: KTVZ (Central Oregon) — read the source article.